GAN Phase I: Global Trend in Burden of Asthma Symptoms in School Children
Introduction
Asthma is the most common chronic disease that adversely impacts children, worldwide. The International Study of Asthma and Allergies in Childhood (ISAAC; Phase I and Phase III) was the only worldwide study that identified the rising prevalence of asthma symptoms in school-aged children in low-income and middle-income countries. Building on the success of ISAAC, the Global Asthma Network (GAN) was established in 2012, in collaboration with the International Union Against Tuberculosis and Lung Disease. One of core activities of GAN’s comprised, GAN Phase I and included global surveillance of prevalence and severity of asthma symptoms. GAN Phase I is believed to be the only source to provide new population-based data on global trends on prevalence of asthma symptoms directly comparable to data from ISAAC Phases I and III.
Aim
To determine the change in the global burden of asthma symptoms, using asthma symptom surveillance in school children
Profile of the Study Participants
- Adolescents (age; 13-14 years) who self-completed the written questionnaire at school.
- Inclusion of children aged 6-7 years in the study was optional. Their questionnaires were completed by their parents or caregivers.
Methods
Study Design
- Multi-center, multinational (conducted across 14 countries), population-based, cross-sectional study
Assessments
- The study employed the same methods as the International Study of Asthma and Allergies in Childhood (ISAAC) Phase III.
- Asthma symptoms were assessed from centres that completed GAN Phase I and ISAAC Phase I (1993–95), ISAAC Phase III (2001–03), or both.
- Information related to current wheeze, severe asthma symptoms, exercise wheeze, and night cough was collected through the questionnaires.
Outcomes
- 10-years change in asthma prevalence (over time from ISAAC Phase I to GAN Phase)
- Estimate of trends in prevalence across the complete 27-year period
Results
- The total study population comprised 1,19,795 participants, of which 74,361 were adolescents (response rate 90%) and 45,434 were children (response rate 79%). Nearly one in ten individuals of both age groups had wheeze in the preceding year. Almost half of these patients with wheeze also had severe symptoms.
- Most centres included in the study, showed a change in prevalence of 2 SE or more between ISAAC Phase III to GAN Phase I.
- Over the period of 27 years, (1993–2020), adolescents showed a significant decrease in percentage point prevalence per decade in severe asthma symptoms (–0·37, 95% confidence interval [CI] –0·69 to –0·04) and an increase in ever having asthma (1·25, 0·67 to 1·83) and night cough (4·25, 3·06 to 5·44). Children also had an increase in night cough (3·21, 1·80 to 4·62).
- The prevalence of current wheeze decreased in low-income countries in children and in adolescents. The prevalence of current wheeze increased in lower-middle-income countries in children and in adolescents, but the same remained stable in upper-middle income and high-income countries (Table 1).
|
|
Outcomes |
Number of surveys* in strata | ||||
|
|
Current wheeze |
Severe asthma symptoms |
Exercise wheeze |
Night cough |
Asthma ever |
|
|
Model stratified by age group and income group | ||||||
|
Age 6–7 years | ||||||
|
Low income |
–1·37 (–2·47 to –0·27) |
–0·84 (–1·37 to –0·30) |
–0·02 (–1·54 to 1·50) |
3·33 (1·34 to 5·32) |
–1·56 (–2·48 to –0·65) |
31 |
|
Lower-middle income |
1·99 (0·33 to 3·66) |
1·32 (0·51 to 2·12) |
3·66 (1·36 to 5·96) |
5·29 (2·28 to 8·29) |
0·06 (–1·33 to 1·44) |
15 |
|
Upper-middle income |
0·50 (–0·82 to 1·82) |
0·20 (–0·44 to 0·84) |
1·66 (–0·17 to 3·48) |
1·41 (–0·98 to 3·80) |
1·19 (0·09 to 2·28) |
43 |
|
High income |
–0·22 (–1·24 to 0·80) |
–0·39 (–0·88 to 0·11) |
0·25 (–1·16 to 1·66) |
3·48 (1·63 to 5·32) |
2·07 (1·22 to 2·92) |
72 |
|
Age 13-14 years | ||||||
|
Low income |
–1·67 (–2·70 to –0·64) |
–1·03 (–1·53 to –0·53) |
–0·58 (–2·00 to 0·85) |
4·31 (2·45 to 6·17) |
–0·84 (–1·70 to 0·02) |
47 |
|
Lower-middle income |
1·69 (0·13 to 3·25) |
1·13 (0·37 to 1·88) |
3·10 (0·95 to 5·25) |
6·26 (3·46 to 9·07) |
0·78 (–0·52 to 2·08) |
40 |
|
Upper-middle income |
0·19 (–1·06 to 1·45) |
0·01 (–0·60 to 0·62) |
1·10 (–0·63 to 2·83) |
2·38 (0·12 to 4·65) |
1·91 (0·86 to 2·95) |
62 |
|
High income |
–0·52 (–1·47 to 0·43) |
–0·58 (–1·04 to –0·12) |
–0·31 (–1·62 to 1·00) |
4·45 (2·73 to 6·17) |
2·79 (2·00 to 3·58) |
106 |
Data represents absolute percentage points difference (95% confidence interval) as compared with ISAAC
*N=number of surveys contributing to each stratified analysis
Conclusions
- GAN phase I provided the first standardized global estimates of trend over time in prevalence and severity of asthma symptoms in school children and adolescents.
- The prevalence and severity of symptoms varied over the past three decades by age group, country income, region, as well as centre.
- Enabling access to effective therapies for asthma would mitigate the high global burden of severe asthma symptoms in children.
Lancet 2021; 398: 1569–80









